Medtronic Q2 FY24 revenue up 5.3% to $7.984B; GAAP EPS $0.68, non-GAAP $1.25; raises FY24 guidance

Medtronic plc

2024-Q2 EPS reported $1.28 revenue$15,686,000,000

Revenue $7.984B, +5.3% reported / +5.0% organic; GAAP net income $909M ($0.68 EPS) +113%; non-GAAP EPS $1.25.
Cardiovascular revenue $2.923B (+5.9%); Neuroscience $2.288B (+4.7%); Medical Surgical $2.142B (+7.0%); Diabetes $610M (+9.7%).
Raises FY24 organic revenue growth guidance to 4.75% (from 4.5%) and non-GAAP EPS guidance to $5.13–$5.19 (from $5.08–$5.16).
FDA approvals for Aurora EV-ICD and Symplicity Spyral RDN; CE Marks for Evolut FX TAVR, Simplera CGM, PulseSelect PFA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Medtronic plc reported second quarter of fiscal year 2024 results: revenue Revenue of $8.0 billion. Guidance raised.

Period: second quarter of fiscal year 2024
Revenue: Revenue of $8.0 billion
Guidance: raised
Result: reported results

Exact text from the filing

2023 – Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights • Revenue of $8.0 billion increased 5.3% as reported and 5.0% organic • GAAP diluted earnings per share (EPS) of $0.68; non-GAAP diluted EPS of $1.25 • Underlying business fundamentals are strong with

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Medtronic plc filing history →

Source: SEC EDGAR

accession 0001613103-23-000144

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.